Luye Pharma Group Ltd., Luye Pharma (USA) Ltd., Shandong Luye Pharmaceutical Co., Ltd., and Nanjing Luye Pharmaceutical Co., Ltd. v. Alkermes Pharma Ireland Ltd. and Alkermes Controlled Therapeutics, Inc.
On November 28, 2017, the Patent Trial and Appeal Board ruled in favor of Fitzpatrick’s clients Alkermes Pharma Ireland Ltd. and Alkermes Controlled Therapeutics, Inc. (collectively “Alkermes”), denying a request by Luye Pharma Group Ltd. et al. to invalidate several claims of U.S. Patent No. 6,667,061.
The Board agreed with Alkermes that Luye failed to demonstrate by a preponderance of the evidence that claims of the ‘061 patent are unpatentable as obvious. Those claims cover the use of Alkermes and Janssen/J&J’s Risperdal Consta® (risperidone) product to treat schizophrenia and bipolar disorder, Alkermes’ Vivitrol® (naltrexone) product to treat alcohol and opioid dependence, and Alkermes and AstraZeneca’s Bydureon® (exenatide extended-release) product to treat type 2 diabetes.
Alkermes was represented by Fitzpatrick attorneys Ha Kung Wong, Scott K. Reed, Melinda Roberts, Una Fan and Jordan Klimek.